Bluebirdbio (NASDAQ:BLUE) Receives a Downgrade In a very recent research note announced on Monday morning, expert analysts at BofA Merrill’s equity division cut the rating…
Bluebirdbio (NASDAQ:BLUE) Receives a Downgrade Morgan Stanley downgraded shares of Bluebirdbio (NASDAQ:BLUE) stock from a “Overweight” rating to a “Equal-Weight” rating in a recent research…
Bluebirdbio (NASDAQ:BLUE) Receives a Downgrade Morgan Stanley has lowered the rating for shares of Bluebirdbio (NASDAQ:BLUE) to a solid Equal-Weight in an analyst research report…
Bluebirdbio (NASDAQ:BLUE) Receives a Downgrade The Rating of Bluebirdbio (NASDAQ:BLUE) shares have been lowered by BofA Merrill from a “Buy” rating to a “Neutral” rating…
How Wells Fargo Currently Rates Bluebirdbio (NASDAQ:BLUE) Analysts at Wells Fargo commenced coverage coverage for shares of Bluebirdbio (NASDAQ:BLUE) in a recent report revealed on…
How Wells Fargo Currently Rates Bluebirdbio (NASDAQ:BLUE) The broker Wells Fargo has began issuing coverage on Bluebirdbio (NASDAQ:BLUE)’s stock, rating it “Outperform”. This was published…
Why Has ROTH Capital Given Bluebirdbio (NASDAQ:BLUE) a $121.0 Price Target ROTH Capital has just issued a Buy rating for Bluebirdbio (NASDAQ:BLUE) shares. The firm…
Why Has ROTH Capital Given Bluebirdbio (NASDAQ:BLUE) a $121 Price Target Equity analysts at ROTH Capital began issuing coverage on Bluebirdbio (NASDAQ:BLUE) with a key…
